RXRX RECURSION PHARMACEUTICALS, INC.

NEUTRAL Impact: 3/10 Institutional Cluster
Horizon weeks Processed 2d 2h ago
Institutional cluster: 5 buyers, 2 sellers (bullish)

Executive Summary

A cluster of five mega-passive institutions (State Street, Wells Fargo, Schwab, Invesco, Morgan Stanley) added $46.3M in RXRX during Q3 2025, while two sellers (Fidelity and Norges Bank) reduced by $28.5M. The net $17.8M inflow is dominated by passive/index rebalancing, not active conviction, and the cluster is overwhelmingly passive — the signal is weak.

Key Financial Metrics

Direction
accumulating
Buy Value
$147.5M
Sell Value
$28.5M
Net Flow
$17.8M

Institutional Positions

Net institutional flow: $17.8M

▲ Buyers (5)

InstitutionActionChangePosition ValueValue Δ
State Street ADD +63.4% $89.2M $32.6M
Wells Fargo DOUBLED +269.2% $3.9M $2.8M
Schwab ADD +33.1% $16.8M $3.7M
Invesco ADD +31% $2.0M $426.0K
Morgan Stanley ADD +28.1% $35.6M $6.8M

▼ Sellers (2)

InstitutionActionChangePrev ValueValue Δ
Fidelity TRIM -42.2% $28.3M -$12.5M
Norges Bank EXIT -100% $16.0M -$16.0M

Actionable Insight

The cluster is dominated by passive rebalancing, not active thesis-driven buying. The $17.8M net inflow is small relative to market cap. Monitor for any active manager 13F additions or a specific catalyst (pipeline readout, partnership) that could drive conviction buying. The historical calibration suggests high-score reports on RXRX have underperformed — avoid over-weighting this signal.

Key Facts

  • 5 buyers added $46.3M in aggregate; 2 sellers reduced by $28.5M; net inflow of ~$17.8M
  • All 5 buyers are mega-passive managers (State Street, Wells Fargo, Schwab, Invesco, Morgan Stanley) — likely index rebalancing, not active conviction
  • Fidelity trimmed 42.2% of its position, selling $12.5M; Norges Bank fully exited a $16.0M position
  • No active hedge fund or activist manager participated in the cluster
  • Historical calibration shows score-6+ reports on RXRX have low observed win rates (34% at score=6) and negative average alpha at T+20 (-2.04% net)

Financial Impact

Net institutional inflow of ~$17.8M (5 buyers added $46.3M, 2 sellers reduced $28.5M) — small relative to $1.6B market cap (~1.1% of float)

institutional ownershipfloat

Risk Factors

  • Passive inflows may reverse next quarter on index reconstitution
  • Norges Bank's full exit and Fidelity's large trim suggest institutional skepticism
  • Historical RXRX reports show negative average alpha at T+20 (-2.04%) — cluster signal may not translate to near-term outperformance

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
57% bullish (14 analysts)

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-RXRX-2025-Q3
9 reports for RXRX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for RXRX — sortable, filterable
Type Now
Jun 11, 2026
2d ago
Institutional Cluster
NEUTRAL ★ 3/10
$3.10 awaiting T+5awaiting T+5
Jun 5, 2026
7d ago
Insider Cluster
NEUTRAL ★ 2/10
$3.32 awaiting T+5awaiting T+5
May 29, 2026
14d ago
Press Release
NEUTRAL ★ 2/10
$3.79 $3.32▼ −12.53%▼ −9.78%
May 6, 2026
5w ago
Press Release
MIXED ★ 6/10
$3.43 $3.15▼ −8.16%▼ −9.29%
May 5, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$3.37 $3.26▼ −3.26%▼ −5.25%
Apr 7, 2026
9w ago
Insider Cluster
NEUTRAL ★ 3/10
$3.19 $3.54▲ +10.97%▲ +5.64%
Mar 25, 2026
11w ago
Press Release
NEUTRAL ★ 3/10
$3.17 $3.06▼ −3.47%▼ −3.23%
Mar 17, 2026
12w ago
Insider Cluster
NEUTRAL ★ 3/10
$3.42 $3.17▼ −7.31%▼ −4.66%
Feb 25, 2026
15w ago
8-K
BULLISH ★ 8/10
$3.77 $3.64▼ −3.45%▼ −2.35%
Showing 9 of 9

US Market Status

Market Closed — Opens Mon (46h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access